Neurotrophic Factors, Impulsivity, and Reward Sensitivity in Children With Internet Gaming Disorder
Investigation of the Relationship Between Serum BDNF and GDNF Levels and Impulsivity, Reward/Punishment Sensitivity in Children Diagnosed With Internet Gaming Disorder
Istanbul Saglik Bilimleri University
120 participants
May 1, 2026
OBSERVATIONAL
Conditions
Summary
Research and knowledge regarding the neurobiology of behavioral addictions and Internet Gaming Disorder (IGD) remain limited compared to substance and alcohol use disorders. However, IGD is increasingly causing significant functional impairment, particularly in the child and adolescent population. The primary objective of this study is to measure the serum levels of Brain-Derived Neurotrophic Factor (BDNF) and Glial-Derived Neurotrophic Factor (GDNF)-both known for their roles in neurogenesis and neuroprotective effects-in a patient group aged 10-14 and a healthy control group. Additionally, this study aims to investigate the relationship between these neurotrophic factor levels and disease severity, as well as various behavioral and emotional parameters measured through psychometric assessments, to identify differences between the patient and healthy populations. Researchers will compare IGD patient group with healthy control group, both aged 10-14. Participants and their parents will be asked to fill self-report measures and serum samples of participants will be collected for BDNF and GDNF level measurements. The main questions of the study are: * Is there a difference in serum BDNF and GDNF levels between IGD patient group and healthy controls? * Is there a relation between serum BDNF and GDNF levels and IGD severity? * Is there a difference in impulsivity, reward/punishment sensitivity between IGD patient group and healthy controls * Is there a relation between serum BDNF and GDNF levels and impulsivity, reward/punishment sensitivity scores in IGD patient group?
Eligibility
Inclusion Criteria6
- For IGD Patient Group:
- Age: Being between 10 and 14 years of age. Literacy: Ability to read and write fluently. Informed Consent: Voluntary participation with written informed consent obtained from both the participants and their parents/legal guardians after a comprehensive briefing on the study procedures and scales.
- Diagnostic Criteria: Meeting the DSM-5 diagnostic criteria for Internet Gaming Disorder (IGD) and scoring above the clinical cutoff on the Internet Gaming Disorder Scale-Short Form (IGDS9-SF).
- For Healthy Control Group:
- Age: Children between 10 and 14 years of age. Literacy: Ability to read and write fluently. Clinical Status: No history or current diagnosis of any neuropsychiatric disorder, confirmed through clinical psychiatric assessment.
- Informed Consent: Voluntary participation with written informed consent obtained from both the participants and their parents/legal guardians after a comprehensive briefing on the study procedures and scales.
Exclusion Criteria3
- Comorbid Psychiatric Disorders: Meeting the DSM-5 diagnostic criteria for Autism Spectrum Disorder, Schizophrenia, Bipolar I Disorder, or Bipolar II Disorder.
- Cognitive and Neurological Impairment: Having a moderate to severe intellectual disability and/or a neurological disease in either the child or the caregiver that would impede the ability to understand instructions or provide reliable responses during the interview.
- Lack of Informed Consent: Refusal to participate voluntarily or failure to sign the informed consent/assent form by the children or their parents/legal guardians after receiving a detailed explanation of the study's purpose and the assessment scales to be administered.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants and their parents will undergo a cross-sectional clinical psychiatric interview conducted by a child and adolescent psychiatrist. Following the interview, both participants and their parents will be required to complete a battery of standardized self-report and parent-report psychometric scales. At the conclusion of the clinical assessment, a peripheral venous blood sample will be collected from each participant for serum biochemical analysis of neurotrophic factors (BDNF and GDNF).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07590180